Recombinant Human Siglec-2/CD22 Protein

• Description:

  Recombinant Human Siglec-2/CD22 Protein_x000D_ Catalog number: B2019218_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 50 µg_x000D_ Molecular Weight or Concentration: 76.6 kDa_x000D_ Supplied as: Powder_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -20°C_x000D_ Keywords: SIGLEC-2 Protein, Human; SIGLEC2 Protein, Human_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Zhao L, Li S, Wei X, Qi X, Liu D, Liu L, Wen F, Zhang JS, Wang F, Liu ZL, Cao YJ. A novel CD19/CD22/CD3 trispecific antibody enhances therapeutic efficacy and overcomes immune escape against B-ALL Blood. 2022 Oct 20;140(16):1790-1802._x000D_ 2: Dhillon S. Moxetumomab Pasudotox: First Global Approval Drugs. 2018 Nov;78(16):1763-1767._x000D_ 3: Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. Immunotoxins for leukemia Blood. 2014 Apr 17;123(16):2470-7._x000D_ 4: Shen J, Vallera DA, Wagner CR. Prosthetic Antigen Receptors J Am Chem Soc. 2015 Aug 19;137(32):10108-11._x000D_ 5: Madge PD, Maggioni A, Pascolutti M, Amin M, Waespy M, Bellette B, Thomson RJ, Kelm S, von Itzstein M, Haselhorst T. Structural characterisation of high affinity Siglec-2 (CD22) ligands in complex with whole Burkitt's lymphoma (BL) Daudi cells by NMR spectroscopy Sci Rep. 2016 Nov 3;6:36012._x000D_ 6: Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox Clin Cancer Res. 2011 Oct 15;17(20):6398-405._x000D_ 7: Hanasaki K, Varki A, Powell LD. CD22-mediated cell adhesion to cytokine-activated human endothelial cells. Positive and negative regulation by alpha 2-6-sialylation of cellular glycoproteins J Biol Chem. 1995 Mar 31;270(13):7533-42._x000D_ 8: Kreitman RJ. Immunotoxins for targeted cancer therapy AAPS J. 2006 Aug 18;8(3):E532-51._x000D_ 9: Fancher KM, Lally-Montgomery ZC. Moxetumomab pasudotox: A first-in-class treatment for hairy cell leukemia J Oncol Pharm Pract. 2019 Sep;25(6):1467-1472._x000D_ 10: FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I. Recombinant immunotoxins for treating cancer Int J Med Microbiol. 2004 Apr;293(7-8):577-82. _x000D_ _x000D_ Products Related to Recombinant Human Siglec-2/CD22 Protein can be found at Proteins

• Short Description:

  Catalog Number: B2019218 (50 µg)_x000D_ Recombinant Human Siglec-2/CD22 Protein is a laboratory-produced version of the human CD22 protein, a member of the Siglec family. It is primarily expressed on B cells and plays a crucial role in regulating B cell activation. This product has been used as a molecular tool for various biochemical applications. It has also been used in a wide array of other chemical and immunological applications. Custom bulk amounts of this product are available upon request._x000D_ _x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3